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Pancreatic cancer is one of the most recalcitrant and lethal of all cancers.
We examined the effects of Anemarrhena asphodeloides (AA) and timosapo-
nin-AIII (TAIII), a steroidal saponin present in AA, on pancreatic cancer
cell proliferation and aimed to elucidate their potential apoptotic mecha-
nisms of action. Viability assays and cell cycle analysis revealed that both
AA and TAIII significantly inhibited pancreatic cancer cell proliferation
and cell cycle progression compared to treatment with gemcitabine, the
standard chemotherapeutic agent for advanced pancreatic cancer. We iden-
tified a dose-dependent increase in caspase-dependent apoptosis and activa-
tion of pro-apoptotic PI3K/Akt pathway proteins, with a subsequent
downregulation of pro-survival PI3K/Akt pathway proteins, in pancreatic
cancer cells treated with AA or TAIII over those treated with gemcitabine.
Pancreatic ductal adenocarcinoma (PDAC) is one of
the most lethal cancers with nearly equal incidence
and mortality rates due to a combination of factors
including a lack of early detection methods, limited
surgical options, and ineffective treatment options due
to drug and apoptotic resistance [1]. Surgery remains
the only potential curative therapeutic approach but is
not a viable option for most patients as more than
80% are already in an advanced disease state at the
time of detection [2]. Relapse of the disease is common
in patients whose tumors are initially resectable, ren-
dering chemotherapy a necessity even after surgical
intervention. Standard chemotherapy for advanced
PDAC since 1997 has been the deoxycytidine analog
gemcitabine alone or in combination with nab-Pacli-
taxel or 5-fluorouracil [3]. However, the prognosis in
these patients remains poor due to chemoresistance
resulting in substantial treatment failure in addition to
debilitating side effects [4].
Mutations within a concerted network of several
core cellular signaling pathways can be found through-
out the progression of PDAC [5]. Phosphatidylinosi-
tol-3 kinase (PI3K)/Akt signaling represents one of the
most frequently altered pathways in PDAC and regu-
lates the activity of a litany of substrates involved in
cell survival, proliferation, growth, and motility.
Increased activity of the serine/threonine kinase Akt
promotes cell survival and evasion of apoptosis
Abbreviations
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through the inhibition of pro-apoptotic proteins
including Bcl-2-associated death promoter (BAD) and
the activation of pro-survival substrates and has been
observed in several types of cancers [6,7]. One of the
primary negative regulators of PI3K/Akt activity is
phosphatase and tensin homologue deleted on chromo-
some ten (PTEN); inactivating mutations within PTEN
contribute to the hyperactive state of the PI3K/Akt
pathway and progression of PDAC [8]. Glycogen syn-
thase kinase-3 (GSK-3a/b) plays a critical role in con-
trolling several cell cycle regulators and transcription
factors which affect cell fate. Akt catalyzes the inhibi-
tion of GSK-3 via phosphorylation at Ser21 and Ser9
(on GSK-3a and GSK-3b, respectively) [9]. The mam-
malian target of rapamycin (mTOR) signaling pathway
is also affected by mutational Akt activity through
phosphorylation and activation of the mTORC1 com-
plex. Phosphorylated mTOR promotes cell growth by
enhancing the transcription of growth factor mRNA
via the activation of several substrates, including p70
S6 kinase 1 [10].
The exploration of plants as a source of chemothera-
peutic agents in Western medicine has been active since
the 1950s with the discovery of the vinca alkaloids vin-
blastine and vincristine isolated from Catharan-
thus roseus and the isolation of cytotoxic
podophyllotoxins [11]. The rhizome of Anemar-
rhena asphodeloides Bunge (AA) has been a significant
fixture in Traditional Chinese Medicine for thousands
of years and is the only species in the genus. Its pri-
mary chemical components are steroidal saponins, fla-
vonoids, phenylpropanoids, alkaloids, steroids, organic
acids, and anthraquinones. Most abundant among the
identified constituents are steroidal saponins. Timosa-
ponin-AIII (TAIII) , a steroidal saponin first isolated
from AA by Kawasaki et al. in 1963, has exhibited
pro-apoptotic and antimetastatic efficacy against non-
small-cell lung cancer, melanoma, colorectal carci-
noma, and breast cancer in vitro [12–16]. Although
recent studies suggest AA and its constituents may pos-
sess potent antitumor properties, its prospective use in
the treatment of refractory pancreatic cancer has yet to
be elucidated. In this study, we identified the inhibitory
effects of AA and TAIII on PDAC cell lines in part
through modulation of PI3K/Akt pathway proteins.
Materials and methods
Chemicals and reagents
Timosaponin-AIII (CAS registry number: 41059-79-4) was
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). HPLC analysis by the manufacturer determined
the purity was > 98%. Gemcitabine hydrochloride (CAS
registry number: 122111-03-9) was purchased from Sigma-
Aldrich (St. Louis, MO, USA). HPLC analysis by the man-
ufacturer determined a purity > 98%. Rabbit monoclonal
antibodies against cleaved caspase-3 (Asp175; Cat. 9664),
mouse monoclonal antibody against b-actin (Cat. 3700),
and horseradish peroxidase (HRP)-linked secondary anti-
bodies were purchased from Cell Signaling Technology
(Beverly, MA, USA).
Preparation of AA extract and TAIII stock
Dried extract granules of AA Bunge rhizome were origi-
nally obtained from Tianjiang Pharmaceutical Co. (Jiangsu,
China. Batch number 1005417; corresponds to Chinese
Pharmacopeia specification) and kindly provided to us by
C. Zhang. The dried extract was reconstituted in sterile mQ
water at a ratio of 1 : 4 w/v and mixed on a rocker at
room temperature for 72 h. The solution was centrifuged at
2000 g for 10 min to separate undissolved particles and
sterilized using a 0.2 lm PEM filter. Total protein content
within the extract stock was determined using the Pierce
BCA protein assay (Thermo Fisher Scientific Inc., Wal-
tham, MA, USA). Extract stock was stored at 4 °C and
diluted with sterile mQ water to the indicated concentration
prior to each experiment.
A stock solution of 8 mM TAIII was prepared in DMSO
then diluted with sterile mQ water to a final concentration
of 0.5% DMSO for each treatment condition. Stock solu-
tion was stored at 20 °C.
Determination of TAIII content in AA extract via
LC–MS–TOF
LC–MS analysis was performed using Agilent 1200 series/
6230 TOF liquid chromatography/mass spectrometer with
a SynergiTM 4 lm Hydro-RP LC column (250 9 4.6 mm)
with 80 A pore size. Samples of AA (0.5 mgmL1) and
TAIII (0.1 mgmL1) were run in positive mode at a flow
rate of 1 mL per min using a 14-min gradient of 0–98%
acetonitrile in 0.05% formic acid. TAIII content in the
AA extract was determined by comparison with reference
sample.
Cell culture
PANC-1 and BxPC-3 cells were cultured in growth medium
(Dulbecco’s modified Eagle’s medium with L-glutamine
and RPMI 1640 with L-glutamine, respectively) supple-
mented with 10% FBS and 1% penicillin–streptomycin
(100 unitsmL1 penicillin and 100 lgmL1 streptomycin).
Both PANC-1 and BxPC-3 cell lines were authenticated via
STR profiling (Promega, Madison, WI, USA) and
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confirmed to be an exact match to the indicated cell line by
ATCC (STR12699 and STR12675). Cells were maintained
in a humidified incubator in 5% CO2 at 37 °C.
Cell viability assay
Cell viability was assessed via modified 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide assay using the
CellTiter 96 Non-Radioactive cell proliferation assay (Pro-
mega). Briefly, cells were seeded at 10 000 cells per well in
a 96-well plate and allowed to attach overnight. The cells
were then treated with equal volumes of various concentra-
tions of AA and TAIII, with and without 1 mM gemc-
itabine, 1 mM gemcitabine alone, and sterile mQ water or
0.5% DMSO vehicle control for 24 or 48 h. Absorbance
was measured as optical density (OD) at a wavelength of
570 nm using a VersaMax microplate reader (Molecular
Devices, LLC. Sunnyvale, CA, USA). The OD of vehicle-
treated control cells represented 100% viability. Viability of
treated cells was expressed as a percentage of vehicle-trea-
ted control cells.
Flow cytometric analysis of cell cycle distribution
Cell cycle distribution was determined using propidium
iodide (PI) cellular DNA staining. BxPC-3 cells were seeded
at a density of 1.25 9 106 cells in 5 mL in 25-cm2 flasks
and allowed to attach overnight. The media was then
replaced with fresh media containing each treatment condi-
tion. After 24 h, the cells were harvested and washed then
re-suspended in cold PBS. The cells were added dropwise
to cold 70% ethanol and fixed overnight at 20 °C. Fixed
cells were washed in cold PBS and filtered through a 40-lM
nylon cell strainer to remove aggregates. The cells were
stained at a density of 1 9 106 cells in 500 lL staining
solution (0.1% Triton X-100, 20 lgmL1 PI, and
0.2 mgmL1 DNase-free RNase A in PBS) and incubated
at RT in the dark for 30 min. Intracellular DNA data were
acquired by a BD Accuri C6 cytometer (Becton Dickinson,
San Jose, CA, USA). Debris and doublets were excluded
by gating on forward vs. side scatter-area and forward scat-
ter-area vs. forward scatter-height. Gates were performed
on the control sample and uniformly applied to each sam-
ple. At least 10 000 gated events were used for analysis and
the resulting cell cycle distribution was determined using
FCS EXPRESS 6 software (De Novo Software, Glendale, CA,
USA).
Protein extraction and Western blot analysis
PANC-1 cells were seeded at a density of 1.25 9 106 cells
in 5 mL in 25-cm2 flasks and treated as indicated above.
After collection, standard lysis buffer supplemented with
19 Halt Protease Inhibitor Cocktail (Thermo Fisher
Scientific Inc.) was used to obtain whole cell lysate. The
samples were sonicated, and protein concentrations were
determined using the BCA Protein Assay. Equivalent pro-
tein content was loaded into each lane, separated by SDS/
PAGE (Mini-PROTEAN TGX Pre-Cast gels, 4–20%), and
transferred to PVDF membranes. Membranes were blocked
with 5% nonfat dry milk in Tris-buffered saline with
0.05% Tween-20 (TBST) and probed with primary antibod-
ies against indicated proteins diluted in 5% nonfat dry milk
or BSA in TBST overnight at 4 °C. Blots were then incu-
bated with a HRP-conjugated secondary antibody specific
to the primary antibody in 5% nonfat dry milk in TBST at
RT for 1 h. Signal was detected using SuperSignal West
Pico PLUS Chemiluminescent Substrate (Pierce, Rockford,
IL, USA). Blots were imaged and analyzed using the Amer-
sham Imager 600 and the accompanying IMAGEQUANT TL
8.1 software (GE Healthcare Life Sciences, Pittsburgh, PA,
USA).
Analysis of PI3K/Akt pathway signaling activity
via bead-based multiplex assay
Phosphorylated forms of Akt (Ser473), mTOR (Ser2248),
BAD (Ser136), p70 S6 kinase (Thr389), GSK-3a/b (Ser21/
Ser9), and PTEN (Ser380) were detected in the lysate of
PANC-1 cells treated under the aforementioned conditions
using the Bio-Plex Pro cell signaling Akt panel (Bio-Rad,
Hercules, CA, USA). The only deviation from the given
protocol was the use of 19 Halt Protease Inhibitor Cock-
tail in place of phenylmethylsulfonyl fluoride in the cell
lysis buffer. Analysis was performed using the Luminex
MAGPIX (Luminex, Austin, TX, USA). Percent median
fluorescence intensity (MFI) of each analyte is expressed as
a percentage of the MFI corresponding to the vehicle con-
trol-treated sample.
Statistical analysis
Results presented as mean  SE of the number of indi-
cated independent experiments. Statistical significance was
determined by performing a two-tailed, unpaired Student’s
t-test or one-way ANOVA followed by Tukey’s multiple
comparison post-test in GRAPHPAD PRISM 5.01 (GraphPad
Software, San Diego, CA, USA).
Results
TAIII content in AA extract via LC–MS–TOF
analysis
As TAIII is one of the chemical signatures of AA, and
to relatively compare the activity of the whole extract
with TAIII as a single compound, we first wanted to
confirm the presence of TAIII in our AA extract. We
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employed LC–MS–TOF to compare the ESI-MS spec-
tra of the extract (Fig. 1A; RT: 11.24) to that of the
TAIII reference standard (Fig. 1B; RT: 11.23). Analy-
sis of the standard TAIII sample and the AA extract
showed the protonated molecule at m/z 741.44. Fur-
thermore, fragment ions at m/z 579.38 [MH – Glu]+
and 417.34 [MH – Glu – Gal]+ characteristic of TAIII
are present in both ESI-MS spectra [17].
AA enhances inhibition of pancreatic cancer cells
by gemcitabine
PANC-1 and BxPC-3 cells are resistant to gemcitabine
to varying degrees, with PANC-1 cells exhibiting less
sensitivity than BxPC-3 cells [18]. To determine the
effect of AA alone and in the presence of gemcitabine
on the viability of pancreatic cancer cells, we treated
PANC-1 and BxPC-3 cells for 24 and 48 h with
increasing concentrations of AA or AA and 1 mM
gemcitabine. As shown in Fig. 2, AA exhibited a
dose-dependent decrease in viability of both cell lines.
The viability of PANC-1 cells exposed to 750, 1000,
and 1250 lgmL1 AA alone and with gemcitabine
for 24 and 48 h was substantially decreased compared
to those treated with only gemcitabine (P < 0.001)
(Fig. 2A,B). Co-treatment of 1000 and 1250 lgmL1
AA plus gemcitabine for 24 h was significantly more
effective at inhibiting viability than the same
concentration of AA alone (P < 0.05 or P < 0.01;
Fig. 2A). A marked decrease in cell proliferation
was seen in BxPC-3 cells treated with AA alone and
with gemcitabine at concentrations > 500 lgmL1
(P < 0.05 or P < 0.001; Fig. 2C,D). BxPC-3 cells trea-
ted for 24 h with 500, 750, and 1000 lgmL1 AA
plus gemcitabine exhibited significantly less viability
than those treated with the same concentration of AA
(P < 0.05 or P < 0.01). Taken together, these data
suggest that AA not only inhibits the viability of
PANC-1 and BxPC-3 cells, but it also appreciably
enhances the effect of gemcitabine in a dose-depen-
dent manner.
Effects of TAIII on viability of pancreatic cancer
cell lines
We next wanted to examine the effect of the single
compound TAIII on the viability of PANC-1 and
BxPC-3 cells. As shown in Fig. 3, TAIII dose-depen-
dently inhibited PANC-1 cells (Fig. 3A,B), with the
highest dose reducing the viability after 24 and 48 h to
~ 25% and 19%, respectively. Viability of PANC-1
cells treated for 24 h with 5, 10, and 20 lM TAIII was
significantly less than in those treated with gemcitabine
alone (P < 0.05 or P < 0.001). Simultaneous exposure
of TAIII with gemcitabine also resulted in significant
inhibition of PANC-1 cells compared to gemcitabine,
Fig. 1. TAIII present in AA extract. The presence of timosaponin-AIII in our AA extract was determined by comparing the LC–MS–TOF ESI
spectra of the whole extract (A) to that of the TAIII reference sample (B).
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although not to the same degree as the TAIII-only
samples. BxPC-3 cells treated for 24 h with 10 and
20 lM TAIII alone and 10 lM TAIII with gemcitabine
also exhibited significantly reduced viability compared
to gemcitabine treatment (P < 0.05 or P < 0.01;
Fig. 3C). There was no significant difference observed
in BxPC-3 cells treated for 48 h with TAIII alone or
with gemcitabine compared to gemcitabine alone
(Fig. 3D).
BxPC-3 cell cycle progression is inhibited by AA
and arrested in G1 phase by TAIII
To elucidate the effect of AA and TAIII treatment on
the progression of the cell cycle, BxPC-3 cells treated
with increasing concentrations of either AA or TAIII
for 24 h were fixed and stained with PI and their
DNA content was analyzed by flow cytometry. As
shown in Fig. 4A, AA markedly disrupts the cell cycle.
Fig. 2. AA inhibits viability of PDAC cell
lines and potentiates gemcitabine efficacy.
PANC-1 (A,B) and BxPC-3 (C,D) cells were
incubated with the indicated
concentrations of AA, with and without
1 mM gemcitabine, 1 mM gemcitabine
alone, or vehicle for 24 (A,C) or 48 (B,D) h.
Data from three independent experiments
are expressed as mean  SE. Viability
was calculated as a percentage of the
vehicle-treated control cells. Statistically
significant inhibition was determined
compared to cells treated with
gemcitabine alone (*P < 0.05, **P < 0.01,
***P < 0.001) and between treatment
with AA alone and AA + gemcitabine
(#P < 0.05, ##P < 0.01).
Fig. 3. Effect of TAIII on PANC-1 and
BxPC-3 cell viability. PANC-1 (A,B) and
BxPC-3 (C,D) cells were incubated with
the indicated concentrations of TAIII, with
and without 1 mM gemcitabine, 1 mM
gemcitabine alone, or vehicle for 24 (A,C)
or 48 (B,D) h. Data from three
independent experiments are expressed
as mean  SE. Viability was calculated as
a percentage of the vehicle-treated control
cells. Statistically significant inhibition was
determined compared to cells treated with
gemcitabine alone (*P < 0.05, **P < 0.01,
***P < 0.001).
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DMSOA
B
250 µg • mL-1 AA
750 µg • mL-1 AA 1250 µg • mL-1 AA
DMSO 5 µM TAIII
20 µM TAIII10 µM TAIII
Fig. 4. AA and TAIII induce cell cycle arrest and dysfunction in BxPC-3 cells. Flow cytometric analysis of BxPC-3 cells treated with the
indicated concentrations of AA (A), TAIII (B), or 0.5% DMSO for 24 h. Cell cycle distribution was determined by staining intracellular DNA
with PI. At least 10 000 gated cells used for analysis of each sample. Data shown are representative of three independent experiments.
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Fig. 5. Co-treatment with AA or TAIII enhances ability of gemcitabine to impede BxPC-3 cell cycle progression. Flow cytometric analysis of
BxPC-3 cells treated with the indicated concentrations of AA + 1 mM gemcitabine (A), TAIII + 1 mM gemcitabine (B), or 1 mM gemcitabine
alone for 24 h. Cell cycle distribution was determined by staining intracellular DNA with PI. At least 10 000 gated cells used for analysis of
each sample. Data shown are representative of three independent experiments.
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At 250 lgmL1 AA, there is a greater population of
cells in G1 phase compared to the control sample
(73.90% and 47.17%, respectively), allowing fewer
cells to reach S and G2/M phases. At 750 and
1250 lgmL1 AA, the cells exhibit a drastic shift in
the cycle resulting in a large portion of the cells stal-
ling in the sub-G1 phase (37.68% and 78.90%, respec-
tively) compared to the control (1.89%). Exposure to
increasing concentrations of TAIII for 24 h resulted in
a marked increase in the population of cells in G1
phase (50.06%, 72.92%, and 72.86%) and a subse-
quent decrease in the S and G2/M phase populations
compared to the control (Fig. 4B). Cells treated with
20 lM TAIII exhibit a notable increase in the sub-G1
population compared to the control group (9.29% and
1.89%, respectively).
AA and TAIII improve disruption of BxPC-3 cell
cycle by gemcitabine
Pancreatic cancer is frequently resistant to gemcitabine,
which can be due to several possible mechanisms
including efflux from the cell, downregulation of gemc-
itabine-activating proteins, and upregulation of gemc-
itabine-inactivating proteins [19]. We therefore wanted
to determine whether either AA or TAIII co-treatment
with gemcitabine could have a greater effect on cell
cycle progression than gemcitabine alone. Exposure to
AA and gemcitabine dramatically increased the portion
of cells in the sub-G1 phase when compared to gemc-
itabine alone (Fig. 5A). The co-treated cells also
resulted in a more dramatic shift from the G1 to sub-
G1 populations than those treated with the correspond-
ing concentration of AA alone (Fig. 4A). TAIII plus
gemcitabine resulted in a dose-dependent arrest in G1
phase and subsequent increase in the sub-G1 popula-
tion compared to the gemcitabine-only treated cells
(Fig. 5B). As with AA, co-treatment with TAIII and
gemcitabine resulted in a greater population of cells in
the sub-G1 phase than those treated with TAIII alone
(Fig. 4B). Table 1 summarizes the data from Figs 4
and 5. These results indicate that co-treatment of AA
or TAIII and gemcitabine is more effective at inducing
BxPC-3 cell cycle arrest than treatment with AA,
TAIII, or gemcitabine as a single agent.
AA and TAIII modulate activation of PI3K/Akt
pathway members
To determine the effect of AA and TAIII on the acti-
vation of PI3K/Akt pathway proteins, PANC-1 cells
were treated for 24 h as described above and evaluated
for phosphorylated Akt pathway proteins using the
Bio-Plex pro cell signaling Akt panel. Activation via
phosphorylation of the pro-survival proteins mTOR
and p70 S6 kinase was significantly decreased in
PANC-1 cells treated with AA alone and with gemc-
itabine compared to those in which only gemcitabine
was administered (P < 0.001; Fig. 6D,E). Inhibitory
phosphorylation of the pro-apoptotic proteins PTEN
and BAD was also significantly decreased in PANC-1
cells treated with AA alone and in combination with
gemcitabine compared to cells treated with gemc-
itabine alone (P < 0.01 or P < 0.001; Fig. 6B,C).
While the differences in the expression levels of phos-
phorylated Akt, PTEN, mTOR, BAD, and GSK-3
between cells treated with AA and those treated with
AA in the presence of gemcitabine did not reach statis-
tical significance, there is a clear stepwise and dose-
dependent decrease. This may indicate that even subtle
differences in the activity of these efficient proteins
result in a biological effect before reaching levels of
statistical consequence. In the instance of phosphory-
lated p70 S6 kinase, expression does not appear to dif-
fer between cells treated with AA alone and with AA
in the presence of gemcitabine. It is possible that AA
alters the expression of some cellular targets in such a
drastic manner that it eclipses any effect gemcitabine
may have had. Phosphorylation of BAD, mTOR, and
p70 S6 kinase was significantly decreased in cells trea-
ted with 20 lM TAIII alone and with gemcitabine
compared to gemcitabine alone (P < 0.05 or P < 0.01;
Fig. 6C–E). Similar to the effect seen between treat-
ment with AA and with AA plus gemcitabine, the
levels of phosphorylated BAD between cells treated
with 20 lM TAIII with and without gemcitabine do
not differ statistically, although there may still be a
biologically significant variance. Additionally, there
Table 1. Percentage of total gated cells in each population.
Treatment Sub-G1 G1 S G2/M
DMSO 1.89 47.17 23.10 26.35
AA 250 lgmL1 2.96 73.90 11.01 11.54
AA 750 lgmL1 37.68 41.86 15.42 4.69
AA 1250 lgmL1 78.90 6.52 13.95 0.41
TAIII 5 lM 1.31 50.06 27.24 20.39
TAIII 10 lM 1.77 72.92 11.67 12.95
TAIII 20 lM 9.29 72.86 7.10 10.39
Gemcitabine 1 mM 4.50 67.68 13.26 13.15
AA 250 lgmL1 + 1 mM gem 3.07 73.70 8.01 13.33
AA 750 lgmL1 + 1 mM gem 69.23 14.00 15.42 1.14
AA 1250 lgmL1 + 1 mM gem 83.08 11.83 4.67 0.31
TAIII 5 lM + 1 mM gem 3.93 71.70 10.84 12.84
TAIII 5 lM + 1 mM gem 5.14 76.42 6.28 11.39
TAIII 5 lM + 1 mM gem 22.21 56.12 14.58 6.38
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may still be other causative proteins targeted by AA
and TAIII that we have yet to identify.
AA and TAIII induce caspase-dependent
apoptosis in PANC-1 cells
Based on the combined results of the viability, cell
cycle, and multiplex analysis, we suspected AA and
TAIII elicit a caspase-dependent apoptotic cascade. To
investigate this, the lysates of PANC-1 cells treated
with AA or TAIII alone and in the presence of gemc-
itabine were examined by Western blot analysis for
activated caspase-3. The results showed a clear dose-
dependent increase in active caspase-3 in PANC-1 cells
treated with AA compared to the vehicle-treated con-
trol cells and those treated with only gemcitabine
(Fig. 7). There is a similar trend in the cells treated
with increasing concentrations of TAIII, albeit to a
lesser degree. Interestingly, the level of active caspase-3
in the cells treated with TAIII is slightly greater than
Fig. 6. AA and TAIII in the presence and absence of gemcitabine modulate the activity of Akt signaling pathway members. PANC-1 cells
were treated with 1 mM gemcitabine, AA or TAIII (250, 750, or 1250 lgmL1 and 5, 10, or 20 lM, respectively) alone or with 1 mM
gemcitabine, or vehicle for 24 h. Phosphorylation of several Akt pathway members (A–F) was measured by the magnetic-based cell
signaling multiplex assay. Results from two independent experiments are expressed as the relative percent MFI compared to the vehicle-
treated control for each analyte. Significant differences from the gemcitabine-only treatment are indicated (*P < 0.05, **P < 0.01,
***P < 0.001).
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in the cells treated with both TAIII and gemcitabine
which mirrors the cell viability data seen in Fig. 3;
again this suggests that the presence of gemcitabine
affects the activity of TAIII within the cells. These
results indicate that AA and TAIII initiate apoptosis
in PANC-1 cells via a caspase-dependent mechanism.
Discussion and conclusion
Pancreatic ductal adenocarcinoma is one of the most
highly lethal cancers, and its incidence rate is currently
on the rise. Due to a lack of sensitive and accurate
detection methods, a propensity for metastasis, and
nearly universal drug resistance, the 5-year survival
rate among patients whose tumors have disseminated
at the time of detection is among the lowest of any
cancer [1,20]. In the three decades since the landmark
study that led to gemcitabine as the primary
chemotherapeutic agent for PDAC, progress toward a
more effective and less toxic treatment has been scant.
Recent treatment regimens such as gemcitabine + nab-
Paclitaxel and 5-fluorouracil, leucovorin, irinotecan,
oxaliplatin (FOLFIRINOX) have offered only modest
improvements to overall survival or debilitating side
effects, and therefore, the dire need for effective treat-
ment with low toxicity still remains [21,22].
In recent years, interest in natural products such as
herbal extracts as anticancer agents has gained signifi-
cant traction as they offer a multitude of active com-
pounds and the potential for significant reduction in
the toxicity associated with traditional chemotherapy.
The extract of AA Bunge and its bioactive compound
TAIII have demonstrated anticancer effects in a num-
ber of cancer types; however, neither has been investi-
gated for efficacy against PDAC cell growth and
gemcitabine resistance which we have done in our pre-
sent study. Our results demonstrate that AA and
TAIII markedly inhibit the growth of PANC-1 and
BxPC-3 cells and induce caspase-dependent apoptosis
by modulating the activity of PI3K/Akt pathway pro-
teins involved in cell cycle and proliferation. As seen
in Fig. 2, treatment of PANC-1 and BxPC-3 cells with
AA exhibits a hormetic-like, biphasic dose response
wherein there is a low-dose stimulatory effect and
subsequent inhibition with increasing doses. This
dose-response phenomenon frequently occurs across
biological models as low concentrations of a particu-
lar substance elicit a protective stress response within
the cells, while higher doses overwhelm normal repair
mechanisms and are able to affect the intended recep-
tor or signaling pathway [23,24]. A similar biphasic
dose response can be seen in the results of our multi-
plex analysis examining the expression of phosphory-
lated Akt and PTEN (Fig. 6A,B). Notably, both AA
and TAIII exhibit a greater degree of inhibition in the
PANC-1 cells which harbor an activating G12D
Kirsten rat sarcoma viral oncogene homologue
(KRAS) mutation than in the BxPC-3 cells which
express wild-type KRAS [25]. The results also reveal
that PANC-1 cells subjected to TAIII with gemc-
itabine exhibit less inhibition and modulation of
PI3K/Akt pathway proteins than those treated with
TAIII alone. The opposite trend is true for AA,
where treatment with AA in the presence of gemc-
itabine is more effective than with AA alone. This
could indicate that one or more of the processes by
which these cells resist gemcitabine also, at least par-
tially, affects TAIII. Several mechanisms of gemc-
itabine resistance have been demonstrated in PDAC
cells and tumors, including highly efficient efflux of
the drug due to increased expression of multidrug-
resistant and ATP-binding cassette transporters which
could potentially also affect levels of TAIII within the
cells [26,27].
Fig. 7. Caspase-3 activation in PANC-1 cells treated with AA or TAIII and gemcitabine. The expression of activated caspase-3 was examined
by Western blot analysis of PANC-1 cells treated with AA or TAIII, alone or in combination with 1 mM gemcitabine, 1 mM gemcitabine
alone, or vehicle. Expression of b-Actin used as a loading control. Data shown are representative of three independent experiments.
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Regulation of the cell cycle involves a delicate bal-
ance of several concerted processes whose disruption
is a hallmark of tumor proliferation and drug resis-
tance. Thus, chemotherapeutic agents that can force
cancer cells into an arrested cell cycle and eventually
induce apoptosis are of great interest. Our results
show that AA causes the cells to steadily decrease S
and G2 phase populations, while the majority of cells
enter a sub-G1 phase. Treatment with TAIII leads to
a dose-dependent decrease in S and G2 phase popula-
tions and increased G1 populations, resulting in G1
arrest. Multiplex analysis also revealed that treatment
with AA led to a significant decrease in phosphory-
lated GSK-3a/b and, along with TAIII (20 lM), sig-
nificantly reduced phosphorylation of p70 S6 kinase
in PANC-1 cells compared to treatment with gemc-
itabine. p70 S6 kinase is activated by phosphorylation
and one of its major functions is regulation of cell
growth, and it is required for progression through the
G1 phase [28]. GSK-3 is a critical downstream kinase
in the PI3K/Akt pathway and can be inhibited via
Akt-mediated phosphorylation at Ser21 (GSK-3a)
and Ser9 (GSK-3b) [9]. Under normal conditions,
GSK-3b regulates cyclin D1 turnover and subse-
quently the transition from G1 phase to S phase by
phosphorylation; however, the role of GSK-3a/b in
PDAC remains a topic of controversy as it has
demonstrated both tumor suppressor and oncogenic
effects [29]. The activities of GSK-3 are also highly
dependent upon whether it is located in the cyto-
plasm or nucleus [30]. Taken together, these data
indicate that AA and TAIII disrupt PDAC cell cycle
progression, are concordant with the viability assay
data shown in Figs 2 and 3, and suggest the possibil-
ity of distinct mechanisms of action between AA and
TAIII.
In addition to aberrant cell cycle and growth regula-
tion, PDAC is highly adept at circumventing apoptosis
induction by both intracellular mechanisms and
chemotherapeutic agents. It has been repeatedly
demonstrated that overactivation of the PI3K/Akt
pathway contributes to proliferation and drug resis-
tance in PDAC. Thus, this pathway is an attractive
target in the search for vulnerabilities within PDAC
cells to attenuate resistance and induce apoptosis. Our
results indicate that while the combined effect is not
synergistic, both AA and TAIII singularly and with
gemcitabine are able to inhibit the phosphorylation of
PI3K/Akt pathway proteins and promote apoptosis in
PDAC cells to a much greater extent than gemcitabine
alone.
In summary, the results of our study demonstrate
that AA Bunge and its constituent TAIII modulate the
activity of PI3K/Akt pathway proteins and are potent
inhibitors of PDAC cell proliferation. These findings
demonstrate the importance of further investigation
into the potential antitumorigenic and gemcitabine-
sensitizing properties of AA and TAIII in treating
advanced pancreatic cancer.
Acknowledgements
The authors would like to thank Dr. Meera Nanjundan
and Dr. Stanley Stevens for their insight and contribu-
tions to this work. This research did not receive any
specific grant from private or public funding agencies.
Author contributions
CM, BB, and CZ conceived and designed experiments.
CM, AS, and TS performed experiments and data
analysis. BB supervised research project. CM and BB
wrote the manuscript. All authors read and approved
the final manuscript.
Conflict of interest
The authors declare no conflict of interest.
References
1 Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362,
1605–1617.
2 Xu Q, Zhang TP and Zhao YP (2011) Advances in
early diagnosis and therapy of pancreatic cancer.
Hepatobiliary Pancreat Dis Int 10, 128–135.
3 Burris HR, Moore MJ, Andersen J, Green MR,
Rothenberg ML, Modiano MR, Cripps MC, Portenoy
RK, Storniolo AM and Tarassoff P (1997)
Improvements in survival and clinical benefit with
gemcitabine as first-line therapy for patients with
advanced pancreas cancer: a randomized trial. J Clin
Oncol 15, 2403–2413.
4 Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C,
Yao Q and Li M (2011) Overcoming drug resistance in
pancreatic cancer. Expert Opin Ther Targets 15, 817–828.
5 Yachida S and Iacobuzio-Donahue CA (2013)
Evolution and dynamics of pancreatic cancer
progression. Oncogene 32, 5253–60.
6 Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh
Y and Greenberg ME (1997) Akt phosphorylation of
BAD couples survival signals to the cell-intrinsic death
machinery. Cell 91, 231–241.
7 Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ,
Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV
et al. (2001) AKT1/PKBalpha kinase is frequently
elevated in human cancers and its constitutive
1165FEBS Open Bio 8 (2018) 1155–1166 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
C. B. MarElia et al. Anemarrhena induces pancreatic cancer cell apoptosis
activation is required for oncogenic transformation in
NIH3T3 cells. Am J Pathol 159, 431–437.
8 Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW,
Donahue TR, Dry S and Wu H (2010) PTEN loss
accelerates KrasG12D-induced pancreatic cancer
development. Can Res 70, 7114–7124.
9 Cross DA, Alessi DR, Cohen P, Andjelkovich M and
Hemmings BA (1995) Inhibition of glycogen synthase
kinase-3 by insulin mediated by protein kinase B.
Nature 378, 785–789.
10 Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R
and Hendifar AE (2016) Targeting mTOR in pancreatic
ductal adenocarcinoma. Front Oncol 6, 99.
11 Cragg GM and Newman DJ (2005) Plants as a source
of anti-cancer agents. J Ethnopharmacol 100, 72–79.
12 Jung O, Lee J, Lee YJ, Yun J-M, Son Y-J, Cho JY, Ryou
C and Lee SY (2016) Timosaponin AIII inhibits migration
and invasion of A549 human non-small-cell lung cancer
cells via attenuations of MMP-2 and MMP-9 by
inhibitions of ERK1/2, Src/FAK and b-catenin signaling
pathways. Bioorg Med Chem Lett 26, 3963–3967.
13 Kang YJ, Chung HJ, Nam JW, Park HJ, Seo EK, Kim
YS, Lee D and Lee SK (2011) Cytotoxic and
antineoplastic activity of timosaponin A-III for human
colon cancer cells. J Nat Prod 74, 701–706.
14 Kim KM, Im AR, Kim SH, Hyun JW and Chae S
(2016) Timosaponin AIII inhibits melanoma cell
migration by suppressing COX-2 and in vivo tumor
metastasis. Cancer Sci 107, 181–188.
15 Tsai CH, Yang CW, Wang JY, Tsai YF, Tseng LM,
King KL, Chen WS, Chiu JH and Shyr YM (2013)
Timosaponin AIII suppresses hepatocyte growth factor-
induced invasive activity through sustained ERK
activation in breast cancer MDA-MB-231 cells. Evid
Based Complement Alternat Med 2013, 421051.
16 Kawasaki T and Yamauchi T (1963) Saponins of timo
(ANEMARRHENAE RHIZOMA). II. Structure of
timosaponin A-III. Chem Pharm Bull (Tokyo) 11,
1221–1224.
17 Ma C, Wang L, Tang Y, Fan M, Xiao H and Huang C
(2008) Identification of major xanthones and steroidal
saponins in rat urine by liquid chromatography-
atmospheric pressure chemical ionization mass
spectrometry technology following oral administration
of Rhizoma Anemarrhenae decoction. Biomed
Chromatogr 22, 1066–1083.
18 Fryer RA, Barlett B, Galustian C and Dalgleish AG
(2011) Mechanisms underlying gemcitabine resistance in
pancreatic cancer and sensitisation by the iMiDTM
lenalidomide. Anticancer Res 31, 3747–3756.
19 de Sousa Cavalcante L and Monteiro G (2014)
Gemcitabine: metabolism and molecular mechanisms of
action, sensitivity and chemoresistance in pancreatic
cancer. Eur J Pharmacol 741, 8–16.
20 Siegel RL, Miller KD and Jemal A (2016) Cancer
statistics, 2016. CA Cancer J Clin 66, 7–30.
21 Conroy T, Desseigne F, Ychou M, Bouche O,
Guimbaud R, Becouarn Y, Adenis A, Raoul JL,
Gourgou-Bourgade S, de la Fouchardiere C et al.
(2011) FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med 364,
1817–1825.
22 Von Hoff DD, Ervin T, Arena FP, Chiorean EG,
Infante J, Moore M, Seay T, Tjulandin SA, Ma WW,
Saleh MN et al. (2013) Increased survival in pancreatic
cancer with nab-paclitaxel plus gemcitabine. N Engl J
Med 369, 1691–1703.
23 Calabrese EJ (2013) Hormetic mechanisms. Crit Rev
Toxicol 43, 580–606.
24 Calabrese EJ (2014) Hormesis: a fundamental concept
in biology. Microb Cell 1, 145–149.
25 Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE,
Ngatia J, Scaife CL, Firpo MA and Mulvihill SJ (2010)
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39, 425–435.
26 Bergman AM, Pinedo HM, Talianidis I, Veerman G,
Loves WJP, van der Wilt CL and Peters GJ (2003)
Increased sensitivity to gemcitabine of P-glycoprotein
and multidrug resistance-associated protein-
overexpressing human cancer cell lines. Br J Cancer 88,
1963–1970.
27 Hagmann W, Faissner R, Schnolzer M, Lohr M and
Jesnowski R (2011) Membrane drug transporters and
chemoresistance in human pancreatic carcinoma.
Cancers 3, 106–125.
28 Pullen N and Thomas G (1997) The modular
phosphorylation and activation of p70s6k. FEBS Lett
410, 78–82.
29 Zhang Q, Bhojani MS, Ben-Josef E, Spalding AC,
Kuick R, Sun Y and Morgan MA (2013) Glycogen
synthase kinase 3b in pancreatic cancer and its
implications in chemotherapy and radiation therapy. J
Carcinog Mutagen 4, 147.
30 Zhang JS, Herreros-Villanueva M, Koenig A, Deng Z,
de Narvajas AA, Gomez TS, Meng X, Bujanda L,
Ellenrieder V, Li XK et al. (2014) Differential activity
of GSK-3 isoforms regulates NF-kappaB and TRAIL-
or TNFalpha induced apoptosis in pancreatic cancer
cells. Cell Death Dis 5, e1142.
1166 FEBS Open Bio 8 (2018) 1155–1166 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Anemarrhena induces pancreatic cancer cell apoptosis C. B. MarElia et al.
